DDReg Pharma- Consulting in regulatory affairs and drug safety

Innovations such as real-world evidence (RWE) and emerging data capture technologies are shaping clinical development, leading to next-generation therapies for complex or rare diseases. The pandemic has accelerated drug development processes and increased collaboration between regulatory agencies and the industry.   Regulators are adapting to these changes, calling for new approaches and harmonization among agencies. Regulatory affairs professionals play a crucial role in navigating these complexities, strategically impacting organizations and improving patient care. By embracing innovation and collaboration, they can enhance development strategies and deliver greater value to patients. The article explores how these innovations can streamline regulatory processes, accelerate the delivery of innovative treatments, and shape a more promising future for healthcare. Real-World Evidence (RWE) and Real-World Data (RWD) Real-World Evidence and Real-World Data have emerged as pow...

Introduction & overview The regulatory landscape, including pharma regulatory affairs , has faced major revolution and transformation by adopting the eCTD format across the globe. Electronic submissions are driving efficient product authorizations and approvals for pharmaceutical organizations to stay ahead of the market. Undoubtedly, these benefits of eCTD are enormous- particularly the fact that the eCTD format reduces the time and resources needed for regulatory submissions. Furthermore, it provides enhance management and tracking of the necessary regulatory information while maintaining compliance. But the transition from paper-based submissions to NeeS to eCTD is not as straightforward as it seems as it is associated with many challenges regarding added cost, resources, and time.  Transition to the eCTD One of the main challenges that regulatory professionals face when transitioning to the eCTD is the time and resource it takes. For example, organizations would need to i...

Regulatory agencies are independent governmental bodies established by the legislature to perform and impose specific laws in a specific field of activity. These agencies create, monitor and implement laws and ensure that activities are performed in regulatory compliance . Pharmaceutical regulatory agencies are the regulatory agencies that establish and implement specific laws for pharmaceutical product manufacturing, approval, clinical trials, and other pharmaceutical-related activities. The main objective of pharmaceutical regulatory agencies is to ensure the safety, efficacy, and quality of the drug. Every country has their own pharmaceutical regulatory authorities. Some of the various regulatory agencies are the following: •            Central Drug Standard Control Organization (CDSCO) – India •            European Medicines Agency (EMEA) - Europe •     ...

Pharmaceutical organizations that are not compliant with regulations set by the authorities can face severe consequences that can significantly impact the organization in terms of cost and reputational damage. Regulatory service providers must also ensure that their services and quality systems are compliant with regulations and current good manufacturing practices (cGMP). Companies that are not cGMP compliant or follow strict quality parameters could be problematic and lead to product recall. Therefore, it is important to partner with a pharma regulatory affairs consulting team or service that can, for example, assist in responding to queries or regulatory conc erns or navigate through quality system audits to ensure regulatory compliance is met. When identifying the right regulatory consulting firms it is important to make sure that they possess recent and extensive experience in the regulatory domain. They must also be able to demonstrate their knowledge of the regulatory land...